These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Bai P; Mabley JG; Liaudet L; Virág L; Szabó C; Pacher P Oncol Rep; 2004 Feb; 11(2):505-8. PubMed ID: 14719091 [TBL] [Abstract][Full Text] [Related]
6. [Cardiological monitoring of patients treated with doxorubicin]. Mahaux V; Demoulin JC; Closon MT; Jardon-Jeghers C; Vivario M; Kulbertus H Rev Med Liege; 1988 Jun; 43(12):449-55. PubMed ID: 3041526 [No Abstract] [Full Text] [Related]
7. Unusual case of congestive heart failure: cardiac magnetic resonance imaging and histopathologic findings in cobalt cardiomyopathy. Khan AH; Verma R; Bajpai A; Mackey-Bojack S Circ Cardiovasc Imaging; 2015 Jun; 8(6):. PubMed ID: 26022382 [No Abstract] [Full Text] [Related]
8. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Mettler FP; Young DM; Ward JM Cancer Res; 1977 Aug; 37(8 Pt 1):2705-13. PubMed ID: 872096 [No Abstract] [Full Text] [Related]
9. Plasma endothelin-1 and doxorubicin cardiotoxicity. Yamashita J; Ogawa M; Nomura K N Engl J Med; 1994 Dec; 331(22):1528-9. PubMed ID: 7969316 [No Abstract] [Full Text] [Related]
10. [A heart transplant in a patient with doxorubicin-induced myocardiopathy as a complication of the treatment of a lymphoma]. Rubio JA; Pulpón LA; Cavero MA; Oteo JF; Maicas C; Silva L; Serrano-Fiz S; Burgos R; Artaza M; Téllez G Rev Esp Cardiol; 1994 Nov; 47(11):777-9. PubMed ID: 7800910 [TBL] [Abstract][Full Text] [Related]
11. Bone marrow mononuclear cell transplantation had beneficial effects on doxorubicin-induced cardiomyopathy. Ishida M; Tomita S; Nakatani T; Fukuhara S; Hamamoto M; Nagaya N; Ohtsu Y; Suga M; Yutani C; Yagihara T; Yamada K; Kitamura S J Heart Lung Transplant; 2004 Apr; 23(4):436-45. PubMed ID: 15063403 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of cardiac resynchronization therapy in the management of Doxorubicin-induced cardiomyopathy. Ajijola OA; Nandigam KV; Chabner BA; Orencole M; Dec GW; Ruskin JN; Singh JP Am J Cardiol; 2008 May; 101(9):1371-2. PubMed ID: 18435975 [TBL] [Abstract][Full Text] [Related]
13. [A young man with acute dilated cardiomyopathy]. Tølløfsrud C; Hoel T Tidsskr Nor Laegeforen; 2006 May; 126(10):1338-9. PubMed ID: 16715575 [No Abstract] [Full Text] [Related]
14. [The feature of cardial remodeling process at Doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy]. Katamadze NA; Lartsuliani KP; Begishvili NN; Dundua KhV; Kiknadze MP Georgian Med News; 2006 Jan; (130):61-4. PubMed ID: 16510915 [TBL] [Abstract][Full Text] [Related]
15. Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy. Simsir SA; Lin SS; Blue LJ; Gockerman JP; Russell SD; Milano CA Ann Thorac Surg; 2005 Aug; 80(2):717-9. PubMed ID: 16039240 [TBL] [Abstract][Full Text] [Related]